Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0000899243-23-003939 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-03 | 2023-02-01 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +531.9K | 810.1K | +191% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-01 | A | A | 531,914 | $0.00 | 810,118 | D | — | — | (F1) Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date. (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person. |